Identification of Deferasirox as a Potential Carbonic Anhydrase II Inhibitor for Glaucoma treatment via Virtual Screening
Journal of Ophthalmic and Optometric Sciences · 08.11.2023
DOI: 10.22037/joos.v6i1.42856 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ophthalmic and Optometric Sciences, erschienen am 08.11.2023. Verfasst von Safa Lotfi.
Abstract (Originalsprache)
Background
Systemic or topical administration of sulfonamide-containing carbonic anhydrase (CA) inhibitors is currently one of the lowering IOP approaches to treat glaucoma. Carbonic anhydrase II is an eye-expressed CA isoenzyme and has a major role in aqueous humor production. Material and Methods: To identify new CA II inhibitors, the receptor-based virtual screening was performed using DrugRep server and its FDA-approved drug library. The crystal structure of human CA II (3HS4) was utilized as the receptor. The physicochemical, pharmacokinetic, and drug-likeness properties of 15 top-ranked inhibitors were then investigated by SwissADME server.
Results
The results showed that 200 recognized inhibitors interact with CA II active site with high binding affinities (-10.1 to -7.2 kcal/mol). 9 out of 15 top compounds (antrafenine, doxycycline, sitagliptin, benzhydrocodone, lumacaftor, deferasirox, lemborexant, talazoparib, selinexor, enasidenib, rolapitant, cyclothiazide, bendroflumethiazide, chlorthalidone, and quinupramine) possess fluorine atoms and 3 of them have the sulfonamide group in their structure. Based on the results, deferasirox is suggested as a promising candidate for further studies. This moderately soluble compound, which does not have fluorine atoms or a sulfonamide group in its structure, exhibits high bioavailability and GI absorption. Deferasirox is not a blood-brain barrier permeant and P-glycoprotein substrate and does not inhibit any CYP isoforms.
Conclusion
Deferasirox is suggested as a good candidate for glaucoma treatment. However, many further studies are required in this regard.
Schlagwörter
Zitieren
APA
Lotfi, S. (2023). Identification of Deferasirox as a Potential Carbonic Anhydrase II Inhibitor for Glaucoma treatment via Virtual Screening. Journal of Ophthalmic and Optometric Sciences. https://doi.org/10.22037/joos.v6i1.42856
Vancouver
Lotfi S. Identification of Deferasirox as a Potential Carbonic Anhydrase II Inhibitor for Glaucoma treatment via Virtual Screening. Journal of Ophthalmic and Optometric Sciences. 2023. doi:10.22037/joos.v6i1.42856
BibTeX
@article{Lotfi2023,
author = {Lotfi, Safa},
title = {Identification of Deferasirox as a Potential Carbonic Anhydrase II Inhibitor for Glaucoma treatment via Virtual Screening},
journal = {Journal of Ophthalmic and Optometric Sciences},
year = {2023},
doi = {10.22037/joos.v6i1.42856}
}
EUVIMED